Pharmacokinetics linearity [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2015-05-29 11:03 (4046 d 16:56 ago) – Posting: # 14881
Views: 5,344

Dear PJS
I do not know if I get things right, but IMHO the whole discussion would only make sense if you claim bioequivalence of your BE formulation (25mg/5ml sol which will be tested vs 25 mg tab ) also to the lower tablet strength (i.e. 5mg/1ml sol vs 25 mg tab). But as far as I understood you want to waive the 5mg/5ml strength. This is a different formulation (not dose proportional composition) and consequently you will need another BE study.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
337 visitors (0 registered, 337 guests [including 27 identified bots]).
Forum time: 04:00 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5